Pfizer wraps deal for GSK's meningococcal vaccines; Indivior to fight Sandoz's suboxone copycat plans;

> Pfizer ($PFE) wrapped up its $130 million buyout of two GlaxoSmithKline ($GSK) meningococcal vaccines, Nimenrix and Mencevax. Report

> Indivior plans to sue Novartis' ($NVS) generics unit Sandoz for patent infringement after the latter filed for FDA approval for a copycat version of suboxone sublingual film. Report

> A new Cuban vaccine against hepatitis B is going through the process of clinical evaluation in 8 Asian countries in alliance with the French company Abivax. Report

> Diabetes drugs made by Novo Nordisk ($NVO) in partnership with the Algerian pharma Saidal will begin to be exported from that country beginning next year. Report

And Finally... Following European regulators, Brazil halted the use of breast implants made by a domestic devicemaker Silimed. Report

Suggested Articles

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.